Table 3.

Overall Survival

	Univariate HR (95% CI)	p	Multivariate HR (95% CI)	p
Age at AML relapse (per year)	1.0 (1.004–1.042)	0.01	1.0 (1.001–1.039)	0.04
Time from AML diagnosis to relapse (per month)	0.9 (0.8–0.9)	0.0021	0.97 (0.926–1.023)	0.2
Cycles of consolidation therapy prior to relapse (per cycle)	0.7 (0.5–0.9)	0.004	0.8 (0.6–1.1)	0.2
Hemoglobin at AML relapse	0.8 (0.79–0.97)	0.01	0.8 (0.7–0.9)	0.01
Primary versus secondary AML	0.6 (0.2–1.3)	0.2
Percent blasts at AML relapse	0.99 (0.99–1.007)	0.67
WBC at AML relapse	0.99 (0.986–1.008)	0.57
Platelet count at AML relapse	0.99 (0.99–1.003)	0.69
Cytogenetic risk at AML relapse		0.6
Favorable versus unfavorable	0.6 (0.25–1.6)
Intermediate versus unfavorable	0.9 (0.5–1.7)

HR, hazard ratios; with HR >1.0 corresponding to increased mortality; CI, confidence interval.